Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

被引：0
|
作者：
Garcia-Manero, Guillermo [1 ]
Gore, Steven D. [2 ]
Kambhampati, Suman [3 ]
Scott, Bart L. [4 ]
Tefferi, Ayalew [5 ]
Cogle, Christopher R. [6 ]
Edenfield, William [7 ]
Hetzer, Joel [8 ]
Kumar, Keshava [8 ]
Skikne, Barry S. [9 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA
[3] Univ Kansas Med Ctr, Dept Hematol Oncol, Kansas City, KS USA
[4] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[5] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA
[6] Univ Florida, Gainesville, FL 32611 USA
[7] Canc Ctr Carolinas, Greenville, SC USA
[8] Celgene Corp, Summit, NJ USA
[9] Celgene Corp, Overland Pk, KS USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.424.424
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
424
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
    Garcia-Manero, G.
    Gore, S. D.
    Kambhampati, S.
    Scott, B.
    Tefferi, A.
    Cogle, C. R.
    Edenfield, W. J.
    Hetzer, J.
    Kumar, K.
    Laille, E.
    Shi, T.
    MacBeth, K. J.
    Skikne, B.
    LEUKEMIA, 2016, 30 (04) : 889 - 896
  • [2] Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
    G Garcia-Manero
    S D Gore
    S Kambhampati
    B Scott
    A Tefferi
    C R Cogle
    W J Edenfield
    J Hetzer
    K Kumar
    E Laille
    T Shi
    K J MacBeth
    B Skikne
    Leukemia, 2016, 30 : 889 - 896
  • [3] Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Santini, Valeria
    Almeida, Antonio
    Platzbecker, Uwe
    Jonasova, Anna
    Silverman, Lewis R.
    Falantes, Jose
    Reda, Gianluigi
    Buccisano, Francesco
    Fenaux, Pierre
    Buckstein, Rena
    Campelo, Maria Diez
    Larsen, Stephen
    Valcarcel, David
    Vyas, Paresh
    Giai, Valentina
    Oliva, Esther Natalie
    Shortt, Jake
    Niederwieser, Dietger
    Mittelman, Moshe
    Fianchi, Luana
    La Torre, Ignazia
    Zhong, Jianhua
    Laille, Eric
    de Menezes, Daniel Lopes
    Skikne, Barry
    Beach, C. L.
    Giagounidis, Aristoteles
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (13) : 1426 - +
  • [4] CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia
    Garcia-Manero, Guillermo
    Scott, Bart L.
    Cogle, Christopher R.
    Boyd, Thomas E.
    Kambhampati, Suman
    Hetzer, Joel
    Dong, Qian
    Kumar, Keshava
    Ukrainskyj, Stacey M.
    Beach, C. L.
    Skikne, Barry S.
    LEUKEMIA RESEARCH, 2018, 72 : 79 - 85
  • [5] Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
    Cogle, Christopher R.
    Scott, Bart L.
    Boyd, Thomas
    Garcia-Manero, Guillermo
    ONCOLOGIST, 2015, 20 (12): : 1404 - 1412
  • [6] EFFICACY OF CC-486 (ORAL AZACITIDINE) TREATMENT (TX) IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
    Garcia-Manero, G.
    Savona, M. R.
    Gore, S. D.
    Conkling, P.
    Cogle, C. R.
    Hetzer, J.
    Dong, Q.
    Kumar, K.
    Ukrainskyj, S. M.
    Beach, C.
    Skikne, B. S.
    HAEMATOLOGICA, 2015, 100 : 239 - 239
  • [7] CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH OR WITHOUT PRETREATMENT THROMBOCYTOPENIA
    Garcia-Manero, G.
    Gore, S. D.
    Scott, B. L.
    Savona, M. R.
    Cogle, C. R.
    Boyd, T. E.
    Kambhampati, S.
    Hetzer, J.
    Dong, Q.
    Kumar, K.
    Ukrainskyj, S. M.
    Skikne, B. S.
    HAEMATOLOGICA, 2016, 101 : 15 - 15
  • [8] Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies
    Savona, Michael R.
    Kolibaba, Kathryn
    Conkling, Paul
    Kingsley, Edwin C.
    Becerra, Carlos
    Morris, John C.
    Rifkin, Robert M.
    Laille, Eric
    Kellerman, Amy
    Ukrainskyj, Stacey M.
    Dong, Qian
    Skikne, Barry S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (10) : 1199 - 1206
  • [9] Azacitidine in lower-risk myelodysplastic syndromes
    Santini, Valeria
    LEUKEMIA RESEARCH, 2009, 33 : S22 - S26
  • [10] Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies
    Garcia-Manero, Guillermo
    Doehner, Hartmut
    Wei, Andrew H.
    La Torre, Ignazia
    Skikne, Barry
    Beach, C. L.
    Santini, Valeria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (04): : 236 - 250
12345